INTRODUCTION
============

Venous thromboembolism (VTE) is one of the most important causes of morbidity in medical, surgical, and obstetrics patients as well as those in the ICUs. It is a leading preventable cause of mortality among in-patients ([@B1]). Pulmonary embolism alone is the third most common cause of death from cardiovascular diseases after coronary artery disease and stroke ([@B2]). In 2006, the overall prevalence of VTE in the general population of the United States was 422 per 100,000 and it is estimated to reach 567 per 100,000 people in 2050 ([@B3]).

Up to 70% of VTE cases can be asymptomatic ([@B4]). Moreover, around 6% of cases of DVT and 12% of cases of pulmonary embolism lead to death within one month of diagnosis ([@B5]). Notwithstanding, VTE is treatable and its complications can be avoided safely. Currently, there are many VTE prophylaxis guidelines available. Unfortunately, the guidelines are not utilized properly and many patients with the risk of VTE, who are in need of thromboprophylaxis, do not receive appropriate prophylaxis ([@B6]).

More than 10 centuries ago Avicenna described DVT ([@B7]), but Virchow was the first to mention the three factors contributing to thrombosis namely hypercoagulability, hemodynamic changes (stasis or turbulence) and endothelial injury and/or dysfunction. These 3 factors are now known as Virchow's triad ([@B8]).

Recognizing the epidemiology of VTE is fundamental in its management. This study was designed to determine the prevalence of VTE and its epidemiology in an Iranian adult population.

MATERIALS AND METHODS
=====================

There is no national registry system for keeping VTE records in Iran. Therefore, to statistically calculate the annual prevalence of VTE in case of no prophylaxis, we used the prevalence of VTE in presence of each VTE predisposing condition and the annual prevalence of each VTE predisposing condition in Iran.

On the basis of Virchow's triad, prevalent conditions that predispose patients to VTE include major general surgery, major orthopedic surgery, spinal cord injury, hip fracture, multiple trauma, malignancy, myocardial infarction, congestive heart failure, respiratory failure ([@B1], [@B9]), obesity, immobility, varicose veins, pregnancy and puerperium, oral contraceptive use, specific hereditary conditions ([@B9]), vascular surgery, gynecologic surgery, thoracic surgery, neurosurgery, long-distance travel and critical care ([@B1]).

Prevalence of asymptomatic DVT in each VTE predisposing condition
-----------------------------------------------------------------

We searched the medical literature for studies reporting the prevalence of VTE in presence of each VTE predisposing condition published in the past 10 years. We searched PubMed for every predisposing condition associated with the words "venous thromboembolism" and "prevalence". The most formal reference we found about the VTE prevalence was the 2008 guideline for the prevention of VTE published by the American College of Chest Physicians ([@B1]).

Objective diagnostic screening for asymptomatic DVT in patients not receiving thromboprophylaxis by Geerts et al.([@B1]) yielded the results, which we used as the basis of our study. Since VTE can be asymptomatic in 70% of the cases ([@B4]), and considering the high prevalence of VTE without any thromboprophylaxis, we used these data to achieve practical results. The most important predisposing conditions for DVT and prevalence of DVT in presence of each condition, according to Geerts et al ([@B1]), are described in [Table 1](#T1){ref-type="table"}.

###### 

Approximate risks of DVT in hospitalized patients[^a^](#TFN1){ref-type="table-fn"} ([@B1])

  **Patient group**                                                 **DVT prevalence (%)**
  ----------------------------------------------------------------- ------------------------
  Medical patients                                                  10--20
  General surgery                                                   15--40
  Major gynecologic surgery                                         15--40
  Major urologic surgery                                            15--40
  Neurosurgery                                                      15--40
  Stroke                                                            20--50
  Hip or knee arthroplasty and HFS                                  40--60
  Major trauma                                                      40--80
  Spinal cord injury                                                60--80
  Critical care patients                                            10--80
  Vascular surgery                                                  15--25
  Thoracic surgery[^b^](#TFN2){ref-type="table-fn"}                 18--51
  Coronary artery bypass surgery[^c^](#TFN3){ref-type="table-fn"}   16--48

All rates except for thoracic surgery and coronary artery bypass surgery are based on objective diagnostic screening for asymptomatic DVT in patients not receiving thromboprophylaxis.

Thoracic surgery rate is based on objective diagnostic screening for asymptomatic DVT, but thromboprophylaxis received by patients is not clarified.

Coronary artery bypass surgery rate is based on objective diagnostic screening for asymptomatic DVT and in patients receiving thromboprophylaxis.

DVT: Deep vein thrombosis, HFS: Hip fracture surgery

Annual prevalence of each VTE predisposing condition in Iran
------------------------------------------------------------

To estimate the annual prevalence of each VTE predisposing condition in Iran, we presented to the Department of Statistics and Information Technology (DSIT) of Deputy of Treatment of Iran's Ministry of Health and Medical Education and requested the abovementioned statistics in the past three years. To find out about the population of Iran, we presented to the Statistical Centre of Iran. Statistical Centre of Iran is an official institute affiliated to the Iran's government vice-presidency for strategic planning and supervision. It is the official reference of statistical information dissemination in Iran. According to the Statistical Centre of Iran, the population of the country in the years of 2010, 2011, and 2013 was 74,232,843, 75,149,669 and 76,066,495, respectively ([@B10], [@B11]).

RESULTS
=======

According to the DSIT records, the statistics of hospitalized Iranian adult patients with the risk of DVT, on the basis of categories defined by Geerts et al. ([@B1]), are listed in [table 2](#T2){ref-type="table"}. The average annual number of total adult patients with DVT predisposing conditions in Iran was 5,288,272. Using statistical calculation, approximate prevalence of DVT in presence of each predisposing condition in the hospitalized Iranian adult patients in case of receiving no prophylaxis can be estimated as listed in [table 3](#T3){ref-type="table"}. The mean annual prevalence of DVT in Iran was between 686,928 and 2,089,738 cases. Gynecologic surgery patients were the group with the highest annual DVT rate in these series (minimum of 243,074 and maximum of 648,197 patients annually).

###### 

Number of hospitalized Iranian adult patients with the risk of DVT

                                                         Number of cases in three years               
  ------------------------------------------------------ -------------------------------- ----------- -----------
  Patient group                                          2010                             2011        2012
  Medical patients                                       1,489,771                        1,631,490   1,356,970
  General surgery                                        1,104,401                        1,128,439   962,473
  Major gynecologic surgery                              1,577,426                        1,768,853   1,515,196
  Major urologic surgery                                 175,249                          187,435     173,837
  Neurosurgery                                           145,059                          156,206     145,007
  Hip or knee arthroplasty and HFS                       526                              1,068       940
  Critical care patients                                 647,435                          742,018     604,319
  Vascular surgery                                       12,341                           12,612      11,883
  Thoracic surgery                                       14,336                           15,726      14,487
  Coronary artery bypass surgery or open heart surgery   85,081                           103,923     80,308
  Total                                                  5,251,625                        5,747,770   4,865,420

DVT: Deep vein thrombosis, HFS: Hip fracture surgery

###### 

Approximate prevalence of DVT among the hospitalized Iranian adult patients in three years

  Patient group[^a^](#TFN6){ref-type="table-fn"}                                          2010      2011        2012                            
  --------------------------------------------------------------------------------------- --------- ----------- --------- ----------- --------- -----------
  Medical patients                                                                        148,977   297,954     163,149   326,298     135,697   271,394
  General surgery                                                                         165,660   441,760     169,266   451,376     144,371   384,989
  Major gynecologic surgery                                                               236,614   630,970     265,328   707,541     227,279   606,078
  Major urologic surgery                                                                  26,287    70,100      28,115    74,974      26,076    69,535
  Neurosurgery                                                                            21,759    58,024      23,431    62,482      21,751    58,003
  Hip or knee arthroplasty and HFS                                                        210       316         427       641         376       564
  Critical care patients                                                                  64,744    517,948     74,202    593,614     60,432    483,455
  Vascular surgery                                                                        1,851     3,085       1,892     3,153       1,782     2,971
  Thoracic surgery[^b^](#TFN7){ref-type="table-fn"}                                       2,580     7,311       2,831     8,020       2,608     7,388
  Coronary artery bypass surgery or open heart surgery[^c^](#TFN8){ref-type="table-fn"}   13,613    40,839      16,628    49,883      12,849    38,548
  Total                                                                                   682,296   2,068,307   745,268   2,277,983   633,221   1,922,925

All cases except for thoracic surgery and coronary artery bypass surgery are estimated in case of no thromboprophylaxis.

Thoracic surgery cases are estimated according to undetermined thromboprophylaxis conditions.

Coronary artery bypass surgery cases are estimated in case of receiving thromboprophylaxis.

DVT: Deep vein thrombosis, HFS: Hip fracture surgery, Min: Minimum, Max: Maximum

The annual prevalence rates of DVT among the hospitalized Iranian adult patients at risk of DVT, all hospitalized adult patients and general population are listed in [table 4](#T4){ref-type="table"}. The mean annual prevalence rate of DVT among the hospitalized Iranian adult patients at risk of DVT was approximately between 129.90 and 395.16 cases per 1000 patients. The approximate mean annual prevalence rate of DVT in all hospitalized Iranian adult patients was between 83.24 and 253.23 cases per 1000 patients. The mean annual prevalence rate of DVT in the Iranian general population was estimated to be between 914.08 and 2,780.77 cases per 100,000 people. Since up to 70% of DVT cases can be asymptomatic ([@B4]), approximate annual prevalence rate of symptomatic DVT in the Iranian population is listed in [table 5](#T5){ref-type="table"}.

###### 

Approximate prevalence rate of DVT in the Iranian population in three years

  DVT prevalence                                        2010     2011       2012                         
  ----------------------------------------------------- -------- ---------- -------- ---------- -------- ----------
  Per 1000 hospitalized adult patients at risk of DVT   129.92   393.84     129.66   396.32     130.15   395.22
  Per 1000 hospitalized adult patients                  85.01    257.71     82.96    253.57     81.73    248.19
  Per 100,000 general population                        919.13   2,786.24   991.71   3,031.26   832.46   2,527.95

DVT: Deep vein thrombosis, Min.: Minimum, Max.: Maximum

###### 

Approximate prevalence rate of symptomatic DVT in the Iranian population in three years

  Symptomatic DVT prevalence                            2010     2011     2012                       
  ----------------------------------------------------- -------- -------- -------- -------- -------- --------
  Per 1000 hospitalized adult patients at risk of DVT   38.98    118.15   38.90    118.90   39.04    118.57
  Per 1000 hospitalized adult patients                  25.50    77.31    24.89    76.07    24.52    74.46
  Per 100000 general population                         275.74   835.87   297.51   909.38   249.74   758.39

DVT: Deep vein thrombosis, Min: Minimum, Max: Maximum

DISCUSSION
==========

To our knowledge, this is the first study to estimate the prevalence of VTE among the Iranian population. Our findings are compatible with those of Deitelzweig et al, who estimated the annual prevalence rate of symptomatic VTE in the general population of the United States to be 432 and 453 per 100,000 people in 2010 and 2015, respectively ([@B3]).

Meanwhile, other studies in the United States, Australia, Norway, and Korea have reported different results showing that VTE, DVT and pulmonary embolism have annual prevalence rate ranges of 13.8 to 117, 5.31 to 98, and 7.01 to 34 per 100,000 general population, respectively ([@B12]--[@B15]). This discrepancy might be related to race differences, age standardization, the date of studies and operator-dependent diagnostic methods. Because of our statistical method of calculation and lack of information about the exact age of cases provided by DSIT, age standardization was not possible. Moreover, our study is based on statistical estimation in case of no prophylaxis, while the abovementioned studies included actual cases.

Although the prevalence of VTE in gynecologic patients is not the highest among different patient groups, considering the great number of gynecologic surgeries and the high rate of Cesarean sections which account for 35% of total deliveries in Iran - twice the maximum rate accepted by the WHO ([@B16])- it seems reasonable to argue that Iranian gynecologic patients deserve much more attention and even a special guideline for VTE prophylaxis.

Orthopedic surgery is one of the most important predisposing conditions to VTE ([@B17]). Hip and knee arthroplasty and hip fracture surgery as the most immobilizing orthopedic surgeries are accounted as VTE predisposing factors ([@B1]). Although isolated lower-extremity injuries distal to knee are accounted as a VTE risk factor in the 2008 guideline for prevention of venous thromboembolism published by the American College of Chest Physicians ([@B1]), we were unable to use the data provided by the Iranian Ministry of Health in this regard. That is because the accurate statistics of cases of hip or knee arthroplasty, hip fracture surgery and isolated lower-extremity injuries distal to knee are not reported separately and are included in overall statistics of hospitalization in orthopedic wards and may be even more than what is indicated in [table 2](#T2){ref-type="table"}. We need statistics of isolated cases of lower-extremity injuries distal to knee in the Iranian hospitals for calculation of asymptomatic DVT cases based on the results of 2008 guidelines by Geert et al. ([@B1]). DSIT reports 461,162, 508,507 and 457,111 orthopedic cases in years of 2010, 2011, and 2012, respectively which include cases of isolated lower-extremity injuries distal to knee. This amount of orthopedic cases indicates the serious need for specific attention to VTE prophylaxis and field guided registry in Iran.

The highest prevalence rate of DVT among patient groups belongs to patients with spinal cord injury (SCI) ([@B1]). Rahimi-Movaghar et al. showed in a population based study in Tehran city, that the estimated annual prevalence of traumatic SCI was 4.4 new cases per 100,000 general population and its point prevalence was 44 per 100,000 people; but DSIT does not have any specific records on SCI. According to their findings, it can be estimated that the prevalence of asymptomatic DVT related to traumatic SCI is 26.4 to 35.2 cases per 100,000 Iranian general population ([@B18]).

Studies on the prevalence of VTE in transplantation patients are scarce. Solid organ transplantations not only have a VTE risk similar to major surgeries, but many of them seem to carry specific VTE risks because of particular characteristics of organs transplanted. Prevalence of symptomatic VTE in lung transplantation recipients ranges from 8% to 22% ([@B19]). Additionally, Burns and Iacono have found pulmonary thromboembolism in 27% of autopsies of the lung and heart-lung transplant recipients ([@B20]). The prevalence of VTE in renal transplantation recipients has been reported to vary from 0.6% to 25% ([@B21]). It has also been reported that the prevalence of intraoperative pulmonary embolism in liver transplantation is 4% ([@B22]). According to DSIT records, a total annual number of 5,413 solid organ transplantations are performed in Iran. These data indicate the need for special attention to thromboprophylaxis in transplantation as a VTE risk factor.

Despite the existence of major guidelines on VTE prophylaxis, it is still a leading preventable cause of mortality among in-patients ([@B1]). A large number of patients are missed according to the VTE prevention guideline recommendations ([@B23]). Although there are no clinical trials to be used as reference, it is known that many of these patients need thromboprophylaxis ([@B24]). The abovementioned shortcomings lead researchers to different VTE risk assessment models and subsequently, lead physicians to different practical results. Bikdeli et al. have shown that Goldhaber's risk assessment model and Harinath and St. John's risk assessment models detect only 59.85% and 68.46% of patients at-risk of VTE, respectively in comparison with the guidelines of the American College of Chest Physicians (8^th^ edition) ([@B25]).

There is a significant difference in VTE prophylaxis practice among different countries ([@B23]). At least in developing countries, VTE prophylaxis guidelines like the one by the American College of Chest Physicians are not being implemented correctly ([@B26]). Although thromboprophylaxis guidelines are being applied in Iran, appropriate prophylaxis (in terms of correct type of regimen, dosing, and duration) is given only to 47.60% of patients prone to VTE ([@B27]). Under-prophylaxis and over-prophylaxis are major issues related to VTE in developing countries including Iran ([@B23]). In a study in an Iranian university hospital, we demonstrated that only 63.40% of patients in need of VTE prophylaxis received it ([@B27]). This is consistent with the findings of Heidarnezhad et al, demonstrating under-prophylaxis in Tabriz university hospital wards even in the ICUs ([@B28]). Mokhtari et al. demonstrated that on the basis of the American College of Chest Physicians' guidelines (8^th^ edition), only 78.8% of patients in need of thromboprophylaxis in the Middle Eastern hospitals receive thromboprophylactic drugs ([@B26]).

Moreover, over-prophylaxis is not uncommon in Iran and developing countries. Administration of thromboprophylaxis in patients not in need of it can lead to serious complications. In the Middle Eastern hospitals, 66% of patients with any contraindications to thromboprophylaxis and 78% of patients who do not require any thromboprophylaxis receive inappropriate prophylaxis ([@B26]).

CONCLUSIONS
===========

Evidence suggests that appropriate prophylaxis is not received by all patients in need of it resulting in high prevalence of VTE in Iran. This indicates VTE as a considerable cause of morbidity in the Iranian Hospitals.

Presently, there is no national VTE registry system in Iran. A national registry system based on ICD codes is a basic requirement for evaluating the prevalence of VTE and deciding on how to deal with it. In addition to the urgent need for such a registry system, solving the problems related to under-prophylaxis and over-prophylaxis requires a synchronized guideline-based protocol to be used by the specialist committees in every hospital. Currently we are working to develop an Iranian VTE prophylaxis guidebook (we just released its 2^nd^ edition). We also established a national VTE day in the Persian calendar on which we launch different programs to draw the attention of physicians and the general population to this issue.
